{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30.09","upperLimit":"62.82","value":"46.2"},{"groupId":"OG001","lowerLimit":"8.82","upperLimit":"34.87","value":"19.5"},{"groupId":"OG002","lowerLimit":"9.05","upperLimit":"35.65","value":"20.0"},{"groupId":"OG003","lowerLimit":"0.61","upperLimit":"16.92","value":"5.0"},{"groupId":"OG004","lowerLimit":"5.73","upperLimit":"43.66","value":"20.0"},{"groupId":"OG005","lowerLimit":"3.05","upperLimit":"36.34","value":"14.3"},{"groupId":"OG006","lowerLimit":"8.14","upperLimit":"22.26","value":"14.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"40"},{"groupId":"OG003","value":"40"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"21"},{"groupId":"OG006","value":"106"}],"units":"Participants"}],"description":"CR was determined by investigator at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 centimetres (cm) in in longest transverse diameter (LDi) and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts). As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m\\^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.","id":"OG000","title":"Arm A (Phase II Randomization): Pola+BR in FL"},{"description":"Participants with FL received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 28 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m\\^2, as IV infusion on Day 1 of Cycles 1 to 6.","id":"OG001","title":"Arm B (Phase II Randomization): BR in FL"},{"description":"Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m\\^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.","id":"OG002","title":"Arm C (Phase II Randomization): Pola+BR in DLBCL"},{"description":"Participants with DLBCL received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m\\^2, as IV infusion on Day 1 of Cycles 1 to 6.","id":"OG003","title":"Arm D (Phase II Randomization): BR in DLBCL"},{"description":"Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.","id":"OG004","title":"Arm E (Phase II Expansion): Pola+BG in FL"},{"description":"Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.","id":"OG005","title":"Arm F (Phase II Expansion): Pola+BG in DLBCL"},{"description":"Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m\\^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.","id":"OG006","title":"Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL"}],"paramType":"NUMBER","populationDescription":"ITT population included all randomized participants in Phase II irrespective of whether or not they received the study treatment.","reportingStatus":"POSTED","timeFrame":"6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)","title":"Phase II: Percentage of Participants With CR at PRA Based on CT Only as Determined by Investigator","type":"SECONDARY","unitOfMeasure":"percentage of participants"}